Page last updated: 2024-11-04

salicylsalicylic acid and Albuminuria

salicylsalicylic acid has been researched along with Albuminuria in 2 studies

salicylsalicylic acid: structure
salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.

Albuminuria: The presence of albumin in the urine, an indicator of KIDNEY DISEASES.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Goldfine, AB1
Fonseca, V1
Jablonski, KA1
Pyle, L1
Staten, MA1
Shoelson, SE1

Clinical Trials (5)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Targeting Inflammation to Treat Cardiovascular Aging in Humans (TIVA Study)[NCT01775865]Phase 259 participants (Actual)Interventional2012-09-30Completed
Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD)[NCT00624923]Phase 2/Phase 3340 participants (Actual)Interventional2008-09-30Completed
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate[NCT00799643]Phase 2/Phase 3638 participants (Actual)Interventional2008-11-30Completed
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate[NCT00392678]Phase 2/Phase 3277 participants (Actual)Interventional2006-10-31Completed
Using Salsalate to Target Adipocyte Macrophage Infiltration and Reverse Metabolic Disease Risk in Obese Hispanic Young Adults[NCT02130804]Phase 130 participants (Actual)Interventional2011-07-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Brachial Artery Flow-mediated Dilation (FMD)

Endothelial function (NCT01775865)
Timeframe: Change from baseline brachial artery FMD at 4 weeks

,,
InterventionPercent dilation (Mean)
Baseline4 Weeks
Placebo3.572.50
Salsalate3.494.60
Young Control Group5.88NA

Carotid-femoral Pulse Wave Velocity (CFPWV)

Aortic stiffness (NCT01775865)
Timeframe: Change in CFPWV from baseline at 4 weeks

,,
Interventioncm/sec (Mean)
Baseline4 weeks
Placebo785.1740.01
Salsalate831.3839.6
Young Control Group538.0NA

Change in Cholesterol

secondary (NCT00624923)
Timeframe: Baseline to 30 mo

Interventionmg/dL (Mean)
1- Active Pharmacologic5.1
2- Placebo2.0

Change in Inflammation in the Liver Associated With Nonalcoholic Steatohepatitis (NASH), ALT

Secondary outcome, change in liver inflammation associated with NASH: ALT (NCT00624923)
Timeframe: baseline to 30 mo

InterventionU/L (Mean)
1- Active Pharmacologic-1.1
2- Placebo-0.6

Change in Inflammation Marker: CRP

Secondary outcome of change in inflammation marker CRP (NCT00624923)
Timeframe: baseline to 30 mo

Interventionmg/L (Mean)
1- Active Pharmacologic-0.1
2- Placebo-0.1

Change in Non-calcified Plaque Volume in the Coronary Arteries Assessed by MDCTA From Baseline to 30 Months

(NCT00624923)
Timeframe: Baseline to 30 months

Interventionmm^3 (Mean)
1- Active Pharmacologic0
2-Placebo0

Change From Baseline in Fasting Glucose Over Time.

(NCT00799643)
Timeframe: 48 weeks from baseline

Interventionmg/dl (Mean)
Placebo2.0
Salsalate-13.1

The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 48 From Baseline, Compared Between Treatment Groups.

HbA1c (%, percentage of HbA1c) change from baseline. (NCT00799643)
Timeframe: 48 weeks from baseline

InterventionHbA1c units are % (Mean)
Placebo-0.04
Salsalate-0.33

Change From Baseline and Trends in Fasting Glucose Over Time

(NCT00392678)
Timeframe: 14 week

Interventionmg/dl (Mean)
Placebo13
Salsalate 3.0 g/d-19
Salsalate 3.5 g/d-14
Salsalate 4.0 g/d-15

Change From Baseline in 14-week Insulin, C-peptide, Homeostasis Model [HOMA] Index

HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in insulin from Baseline to Week 14 in data table below. (NCT00392678)
Timeframe: Baseline, week 14

Interventionpmol/l (Median)
Placebo-3.0
Salsalate 3.0 g/d15
Salsalate 3.5 g/d7.6
Salsalate 4.0 g/d27

Change in HbA1c

Change from baseline to either 14 or 26 weeks, or last HbA1c measurement prior to rescue therapy (NCT00392678)
Timeframe: 14 week

Intervention% HbA1c (Mean)
Placebo0
Salsalate 3.0 g/d-0.4
Salsalate 3.5 g/d-0.3
Salsalate 4.0 g/d-0.5

Change in HbA1c Baseline to End of Trial in TINSAL-T2D Stage 1

The primary outcome for the TINSAL-T2D study is change in HbA1c level from baseline to week 14 (stage 1) in the intent-to-treat (ITT) population with last observation carried forward. (NCT00392678)
Timeframe: 14 week

Intervention% (units of HbA1c) (Mean)
3.0 g/d-0.36
3.5 g/d-0.34
4.0 g/d-0.49
Placebo-0.01

Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index

HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in C-peptide from Baseline to Week 14 is in the data table below (NCT00392678)
Timeframe: Baseline, week 14

InterventionC-peptide in nmol/l (Mean)
Placebo0.10
Salsalate 3.0 g/d-0.07
Salsalate 3.5 g/d-0.03
Salsalate 4.0 g/d0.03

Safety and Tolerability

See adverse event module for details. Safety and tolerability of salsalate compared to placebo as assessed by adverse events. (NCT00392678)
Timeframe: 14 weeks

Interventionparticipants (Number)
Salsalate 3.0 g/d17
Salsalate 3.5 g/d16
Salsalate 4.0 g/d16
Placebo14

Change in Lipids

"Change in lipids (low-density lipoprotein cholesterol [LDL-C], non-high-density lipoprotein cholesterol [non-HDL-C], triglycerides [TG], total cholesterol [TC], high-density lipoprotein cholesterol [HDL C], TC/HDL-C ratio, and LDL-C/HDL-C ratio)~LDL-C/HDL-C ratio not calculated" (NCT00392678)
Timeframe: 14 week

,,,
Interventionmg/dl (Mean)
CholesterolHDLLDLTGTotal to HDL ratio
Placebo000150
Salsalate 3.0 g/d8315-340.1
Salsalate 3.5 g/d-113-22-0.1
Salsalate 4.0 g/d628-160.2

Trials

1 trial available for salicylsalicylic acid and Albuminuria

ArticleYear
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010

Other Studies

1 other study available for salicylsalicylic acid and Albuminuria

ArticleYear
Summaries for patients. The effects of salsalate on blood sugar control in people with type 2 diabetes.
    Annals of internal medicine, 2010, Mar-16, Volume: 152, Issue:6

    Topics: Adolescent; Adult; Aged; Albuminuria; Blood Glucose; Diabetes Mellitus, Type 2; Double-Blind Method;

2010